Lineage Cell Therapeutics (LCTX) Net Equity Issued and Repurchased (2011 - 2026)

Lineage Cell Therapeutics' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at -$5.2 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased rose 62.14% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$5.3 million (up 37.86% YoY), while the FY2024 annual figure was $68000.0, down 98.94% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at -$5.2 million, down from $5.2 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $19.9 million in Q1 2021, with the low at -$13.8 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $1.8 million (2021), against an average of $2.7 million.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased tumbled 6845.23% in 2024, then surged 62.14% in 2025.
• Lineage Cell Therapeutics' Net Equity Issued and Repurchased stood at $124000.0 in 2021, then climbed by 19.35% to $148000.0 in 2022, then sank by 234.46% to -$199000.0 in 2023, then sank by 6845.23% to -$13.8 million in 2024, then soared by 62.14% to -$5.2 million in 2025.
• Business Quant data shows LCTX's Net Equity Issued and Repurchased at -$5.2 million in Q4 2025, $5.2 million in Q3 2025, and -$5.3 million in Q2 2025.